In its semiannual drug pricing forecast, healthcare performance company Vizient said that biosimilars will be a key part of combatting rising spending on drugs among its membership.
In its semiannual drug pricing forecast, healthcare performance company Vizient said that biosimilars will be a key part of combatting rising spending on drugs among its membership.
Vizient’s membership currently spends approximately $67 billion on drugs annually, and with a projected 4.28% of drug price inflation, these members are expected to spend another $3 billion annually, even before considering cost increases for new drugs or volume changes.
The top 5 drugs by total spending among Vizient’s membership are adalimumab, infliximab, rituximab, etanercept, and pegfilgrastim, all of which have FDA-approved biosimilars, although only infliximab and pegfilgrastim biosimilars are yet available in the US market. Among these drugs, adalimumab, etanercept, infliximab, and rituximab are all projected to have some of the largest increases in price over the coming year.
As patents for reference products begin to expire, and as more biosimilars are launching in the US market, Vizient says that adopting biosimilars is critical to “combat the costs of these therapies.” In the interest of fostering adoption, Vizient has convened a biosimilars task force to create resources that will help members evaluate biosimilars for formulary inclusion as soon as they launch.
The company has also established a resource webpage for its members that includes evidence-based clinical information on biosimilars, including a soon-to-be-launched financial evaluation tool that members will be able to use to assess the cost and reimbursement impact of adopting different biosimilar-related strategies.
Finally, Vizient says that the market for oncology biosimilars will be “the true test” of whether a biosimilars market in the United States can be sustained, and “it is critically important that we focus our attention on supporting biosimilar evaluation and uptake,” given that spending on rituximab, bevacizumab, trastuzumab, and pegfilgrastim alone account for approximately $14 billion in member spending each year.
HHS Praises Biosimilars Savings but Opportunities to Reduce Part B Spending Remain
November 28th 2023Although biosimilars have already generated savings for Medicare Part B programs and beneficiaries, opportunities for substantial reductions in spending remain, according to a report from the HHS.
Biosimilar Business Roundup for October 2023—Podcast Edition
November 5th 2023On this episode, we discuss the biggest news to come out of October 2023, including 3 regulatory approvals, 2 complete response letters, and new data and industry insights that have the potential to impact the entire US biosimilar industry.
Eye on Pharma: Adalimumab Updates; New Eylea Biosimilar Lawsuit; Canada Gains Stelara Biosimilar
November 22nd 2023Several companies make moves to further their adalimumab biosimilars, Regeneron sues Celltrion over biosimilar for Eylea (aflibercept), and Health Canada grants marketing authorization for biosimilar referencing Stelara (ustekinumab).
Biosimilars Business Roundup For August 2023—Podcast Edition
September 5th 2023On this episode, we’re giving an overview of some of the biggest stories in the business space regarding biosimilars, like the approval of the first neurology biosimilar, growth projections from company quarterly expense reports, and some analyses about the health of the market.
AMCP Nexus: Panelists Share Current Scope of Biosimilar Industry
October 26th 2023Panelists at the Academy of Managed Care Pharmacy (AMCP) Nexus meeting chronicled the current state of the US biosimilar market, including current policies impacting the market, recent regulatory decisions, and the developing arguments around requirements for clinical efficacy studies.
Report: Conflicting Guidelines, Rebate Walls Are Major Factors Determining Biosimilar Uptake
October 24th 2023Samsung Bioepis’ most recent biosimilar market report identified inconsistent medical guidelines, challenges with access and rebates, and acute vs chronic treatment duration as major factors influencing biosimilar uptake in the United States.